期刊
CANCER BIOLOGY & THERAPY
卷 6, 期 1, 页码 11-17出版社
TAYLOR & FRANCIS INC
DOI: 10.4161/cbt.6.1.3672
关键词
colorectal cancer; passive immunotherapy; active immunotherapy; antibodies; vaccines
类别
资金
- NCCIH NIH HHS [R21 AT003094] Funding Source: Medline
- NHLBI NIH HHS [HL08347, HL065916, HL072716] Funding Source: Medline
- NIBIB NIH HHS [EB002436] Funding Source: Medline
- NIDCR NIH HHS [R01 DE15543] Funding Source: Medline
- NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R21AT003094] Funding Source: NIH RePORTER
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065916, R01HL072716, F32HL008347] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB002436] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE015543] Funding Source: NIH RePORTER
Colorectal cancer remains the second leading cause of cancer-related mortality in the United States. Although surgical resection is still the primary treatment for colorectal cancer, in recent years, there has been a remarkable progress in the development of new therapies to treat colorectal cancer. Response rates have increased substantially and new immunotherapeutic approaches are shedding new light in the battle against the disease. This review will focus on the current immunotherapeutic approaches being developed and will discuss clinical data for some of these new treatments.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据